Yep Daub you've got it right. In my mind these small successes are cumulative. Each and every step in itself is noteworthy, but as they add up, the result will be significant. Long and strong, GO IPIX
58's response was right on as well as your post. It is, at this point, cumulative. Every trial has been successful so far. The right data set from the current batch of trials triggers the competition, not just the pharma that has been guiding Innovative Pharmaceutical through CDA's from the beginning. I think the blinded trials for prurisol and brilacidin carry the most potential. Right on target to make a very big move imo. That data set triggers the to do their due diligence on the other trials.
I can already hear shorts sizzling in the frying pan.
News 
Market Data 
Discover 
AI
